These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 19906049)
1. Cardiovascular effects of azelnidipine in comparison with those of amlodipine assessed in the halothane-anaesthetized dog. Ishizaka T; Takahara A; Iwasaki H; Mitsumori Y; Kise H; Nakamura Y; Sugiyama A Basic Clin Pharmacol Toxicol; 2010 Feb; 106(2):135-43. PubMed ID: 19906049 [TBL] [Abstract][Full Text] [Related]
2. Chronotropic effects of azelnidipine, a slow- and long-acting dihydropyridine-type calcium channel blocker, in anesthetized dogs: a comparison with amlodipine. Fujisawa M; Yorikane R; Chiba S; Koike H J Cardiovasc Pharmacol; 2009 Apr; 53(4):325-32. PubMed ID: 19295444 [TBL] [Abstract][Full Text] [Related]
3. The pharmacological differences in antianginal effects of long-lasting calcium channel blockers: azelnidipine and amlodipine. Fujisawa M; Yorikane R; Matsuoka Y; Koike H; Ueno K J Cardiovasc Pharmacol; 2013 Jan; 61(1):63-9. PubMed ID: 23288106 [TBL] [Abstract][Full Text] [Related]
4. Effects of a new calcium channel blocker, azelnidipine, on systemic hemodynamics and renal sympathetic nerve activity in spontaneously hypertensive rats. Shokoji T; Fujisawa Y; Kiyomoto H; Rahman M; Sun GP; Fan YY; Kimura S; Kohno M; Abe Y; Nishiyama A Hypertens Res; 2005 Dec; 28(12):1017-23. PubMed ID: 16671342 [TBL] [Abstract][Full Text] [Related]
5. Azelnidipine attenuates cardiovascular and sympathetic responses to air-jet stress in genetically hypertensive rats. Nakamoto M; Ohya Y; Sakima A; Yamazato M; Takishita S Hypertens Res; 2007 Apr; 30(4):359-66. PubMed ID: 17541215 [TBL] [Abstract][Full Text] [Related]
6. Effects of new calcium channel blocker, azelnidipine, and amlodipine on baroreflex sensitivity and ambulatory blood pressure. Eguchi K; Tomizawa H; Ishikawa J; Hoshide S; Fukuda T; Numao T; Shimada K; Kario K J Cardiovasc Pharmacol; 2007 Jun; 49(6):394-400. PubMed ID: 17577104 [TBL] [Abstract][Full Text] [Related]
7. Efficacy of azelnidipine on home blood pressure and pulse rate in patients with essential hypertension: comparison with amlodipine. Yamagishi T Hypertens Res; 2006 Oct; 29(10):767-73. PubMed ID: 17283863 [TBL] [Abstract][Full Text] [Related]
8. Azelnidipine decreases sympathetic nerve activity via antioxidant effect in the rostral ventrolateral medulla of stroke-prone spontaneously hypertensive rats. Konno S; Hirooka Y; Araki S; Koga Y; Kishi T; Sunagawa K J Cardiovasc Pharmacol; 2008 Dec; 52(6):555-60. PubMed ID: 19057394 [TBL] [Abstract][Full Text] [Related]
9. Azelnidipine attenuates glomerular damage in Dahl salt-sensitive rats by suppressing sympathetic nerve activity. Nagasu H; Satoh M; Fujimoto S; Tomita N; Sasaki T; Kashihara N Hypertens Res; 2012 Mar; 35(3):348-55. PubMed ID: 22072106 [TBL] [Abstract][Full Text] [Related]
10. Long-acting calcium channel blocker, azelnidipine, increases endothelial nitric oxide synthase in the brain and inhibits sympathetic nerve activity. Kimura Y; Hirooka Y; Sagara Y; Sunagawa K Clin Exp Hypertens; 2007 Jan; 29(1):13-21. PubMed ID: 17190727 [TBL] [Abstract][Full Text] [Related]
11. Prevention of neuronal damage by calcium channel blockers with antioxidative effects after transient focal ischemia in rats. Lukic-Panin V; Kamiya T; Zhang H; Hayashi T; Tsuchiya A; Sehara Y; Deguchi K; Yamashita T; Abe K Brain Res; 2007 Oct; 1176():143-50. PubMed ID: 17904110 [TBL] [Abstract][Full Text] [Related]
12. Enhancement of cardiac oxidative stress by tachycardia and its critical role in cardiac hypertrophy and fibrosis. Yamamoto E; Lai ZF; Yamashita T; Tanaka T; Kataoka K; Tokutomi Y; Ito T; Ogawa H; Kim-Mitsuyama S J Hypertens; 2006 Oct; 24(10):2057-69. PubMed ID: 16957567 [TBL] [Abstract][Full Text] [Related]
13. Clinical study with azelnidipine in patients with essential hypertension. Antiarteriosclerotic and cardiac hypertrophy-inhibitory effects and influence on autonomic nervous activity. Nada T; Nomura M; Koshiba K; Kawano T; Mikawa J; Ito S Arzneimittelforschung; 2007; 57(11):698-704. PubMed ID: 18193691 [TBL] [Abstract][Full Text] [Related]
14. Effects of azelnidipine on the autonomic functions and its influence on arterial stiffness and endothelial functions. Yamada J; Tomiyama H; Matsumoto C; Yoshida M; Shiina K; Yamashina A J Cardiol; 2008 Apr; 51(2):114-20. PubMed ID: 18522784 [TBL] [Abstract][Full Text] [Related]
15. [Pharmacological profiles and clinical effects of azelnidipine, a long-acting calcium channel blocker]. Sada T; Saito H Nihon Yakurigaku Zasshi; 2003 Dec; 122(6):539-47. PubMed ID: 14639008 [TBL] [Abstract][Full Text] [Related]
16. Comparative effects of azelnidipine and amlodipine on myocardial function and mortality after ischemia/reperfusion in dogs. Kano S; Ichihara K; Komatsu K; Satoh K J Pharmacol Sci; 2011; 116(2):181-7. PubMed ID: 21597238 [TBL] [Abstract][Full Text] [Related]
17. Differential effects of azelnidipine and amlodipine on sympathetic nerve activity in patients with primary hypertension. Inomata J; Murai H; Kaneko S; Hamaoka T; Ikeda T; Kobayashi D; Usui S; Furusho H; Sugiyama Y; Takata S; Takamura M J Hypertens; 2014 Sep; 32(9):1898-904. PubMed ID: 24979307 [TBL] [Abstract][Full Text] [Related]
18. Comparative effects of azelnidipine and other Ca2+-channel blockers on the induction of inducible nitric oxide synthase in vascular smooth muscle cells. Ma J; Kishida S; Wang GQ; Meguro K; Imuta H; Oonuma H; Iida H; Jo T; Takano H; Morita T; Nagai R; Nakajima T J Cardiovasc Pharmacol; 2006 Feb; 47(2):314-21. PubMed ID: 16495772 [TBL] [Abstract][Full Text] [Related]
19. Effect of azelnidipine and amlodipine on single cell mechanics in mouse cardiomyocytes. Iribe G; Kaihara K; Ito H; Naruse K Eur J Pharmacol; 2013 Sep; 715(1-3):142-6. PubMed ID: 23747592 [TBL] [Abstract][Full Text] [Related]
20. Calcium channel blocker azelnidipine reduces glucose intolerance in diabetic mice via different mechanism than angiotensin receptor blocker olmesartan. Iwai M; Li HS; Chen R; Shiuchi T; Wu L; Min LJ; Li JM; Tsuda M; Suzuki J; Tomono Y; Tomochika H; Mogi M; Horiuchi M J Pharmacol Exp Ther; 2006 Dec; 319(3):1081-7. PubMed ID: 16990512 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]